Cardiogen

What is Cardiogen?

Cardiogen is a synthetic short peptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, positioned in the catalog as the myocardial / heart-muscle tissue-specific entry. It is the tetrapeptide Ala-Glu-Asp-Arg (AEDR), patented by Khavinson's group as a 'peptide substance restoring myocardium function', and it parallels the naming convention of other Khavinson tissue-targeted short peptides (Vesugen / KED for vasculature, Livagen / KEDA for liver and immune, Cortagen / AEDP for cortex). The underlying claim is that Cardiogen selectively interacts with cardiac tissue and modulates gene expression patterns in aging cardiomyocytes, with proposed applications in age-related cardiac function decline, post-infarct recovery, and heart-muscle regeneration. The PubMed-indexed evidence specific to Cardiogen is small — only a handful of Khavinson-group or Russian-collaborator studies in rodent myocardial and tumor-modifying models — and independent Western replication is essentially absent. The sequence itself is settled in the primary sources: the group's US patent claims Ala-Glu-Asp-Arg, and its own reviews list 'Cardiogen (AEDR)'. The tripeptide Ala-Glu-Asp (AED) often attached to Cardiogen online actually belongs to Cartalax, the group's cartilage peptide — a mix-up that still runs through vendor listings and is part of the honest caveat on any product sold under this name.

What Cardiogen Is Investigated For

Cardiogen is studied within the Khavinson bioregulator framework as the heart-tissue counterpart to the other organ-specific short peptides (Livagen for liver, Vesugen for vasculature, Cortagen for cortex) and is discussed for age-related cardiac function decline, post-infarct recovery, and cardiomyocyte support. The available peer-reviewed Cardiogen-specific evidence is small and concentrated in Russian-language or Russian-authored journals: an organotypic tissue-culture study in which Cardiogen stimulated cell proliferation in heart-muscle explants from both young and old rats and lowered the cell-death protein p53, a study in old rats with transplanted M-1 sarcoma in which Cardiogen slowed tumor growth, a mouse-fibroblast study showing increased structural-protein production, plus the broader tissue-specificity literature that groups Cardiogen with other Khavinson short peptides. There are no PubMed-indexed randomized controlled trials in humans for any cardiovascular indication, no independent Western preclinical replication of the myocardial-regeneration claim, and no characterized human pharmacokinetics. Vendor and forum claims around post-infarct recovery, heart failure, or cardiac regeneration in humans significantly exceed what that evidence base can independently support. Cardiogen is sold as a research chemical or as Kardiogen capsules, registered in Russia as a dietary supplement, depending on the channel, and has no FDA approval, no EMA approval, and no formal registration as a Western prescription medicine.

History & Discovery

Cardiogen is one of the organ-specific short peptide entries in the Khavinson bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, led by Vladimir Khavinson. The program's methodology, laid out across decades of Russian-language publications and a smaller set of English-language reviews, was to take tissue-specific complex extracts from animal organs (thymus, pineal, liver, prostate, heart, etc.), fractionate them to identify putatively active short-peptide components, and then synthesize chemically defined short peptides claimed to reproduce the tissue-targeting effect. Cardiogen occupies the myocardial slot in this catalog . It is the tetrapeptide Ala-Glu-Asp-Arg (AEDR), filed for a Russian patent in June 2004 and granted a US patent (7,662,789) in February 2010 as a 'peptide substance restoring myocardium function'. The patent presents it as a cleaner alternative to an older polypeptide preparation obtained from animal heart, and Khavinson's group later described AEDR as an active component of the heart polypeptide complex. The natural calf-heart extract in the same product family is sold as Chelohart. Kardiogen capsules were registered in Russia as a dietary supplement in February 2008. The PubMed-indexed literature on Cardiogen specifically is modest compared to flagship Khavinson entries like Epithalon or Thymalin: a handful of organotypic tissue-culture studies, a study in old rats with sarcoma, a mouse-fibroblast protein study, cell-free histone-binding work, and inclusion in broader reviews. The most detailed heart data (rat heart-attack, isolated-heart, arrhythmia and toxicity experiments) sit in the patent rather than in peer-reviewed papers. Independent Western preclinical replication by cardiology or structural-biology laboratories has not materialized, and there is no PubMed-indexed human clinical trial for Cardiogen in any cardiovascular indication. The peptide reaches Western users almost exclusively through research-chemical lyophilized vials labeled 'not for human use' or through Russian-market Kardiogen oral capsules registered as a dietary supplement — neither of which represents validated therapeutic use, and neither of which is regulated to the evidence standard that would normally accompany a drug for a cardiovascular indication.

How It Works

Cardiogen is proposed to act as a 'tissue-specific' short peptide that selectively interacts with heart-muscle cells and nudges their gene expression toward a healthier, younger pattern. The idea is that as the heart ages, genes involved in cardiomyocyte maintenance and repair become progressively silenced; a short peptide with the right sequence is claimed to bind DNA regulatory regions and reactivate some of those programs, supporting cell proliferation and survival in aged myocardium. This is the same general framework the Khavinson program applies to all its tissue-targeted short peptides — the specific details for cardiac tissue are much less established than for the better-studied members of the catalog.

Within the Khavinson bioregulator framework, Cardiogen (Ala-Glu-Asp-Arg) is proposed to act through direct interaction with DNA regulatory regions and histone proteins in cardiomyocytes, modulating chromatin accessibility and gene expression patterns in aging heart tissue. In an organotypic tissue-culture study (Chalisova et al., Adv Gerontol 2009), Cardiogen at a very low concentration (10^-12 M) strongly stimulated cell proliferation in heart-muscle explants from both 3-month-old and 24-month-old rats and lowered p53, a protein that drives programmed cell death, which the authors read as Cardiogen inhibiting apoptosis. (The age difference in that paper concerned free amino acids, not Cardiogen.) The broader tissue-specificity literature (Zakutskii et al., Adv Gerontol 2006) tested Cardiogen alongside Bronchogen, Prostamax and Pancragen on heart, lung, prostate and pancreas explants, claiming each short peptide preferentially activates cells of its named target tissue through sequence-specific DNA recognition — though a concrete molecular mechanism for how a four-residue peptide achieves tissue-specific gene regulation has not been established even within the Khavinson literature and has not been independently validated by Western structural biology or chromatin research. A study in old rats with transplanted M-1 sarcoma (Levdik and Knyazkin, Bull Exp Biol Med 2009) reported that Cardiogen injections inhibited tumor growth in a dose-dependent way, through hemorrhagic necrosis and more tumor-cell apoptosis rather than a direct toxic effect on tumor cells, and proposed that it acted through the tumor's blood vessels. This single, unreplicated result sits awkwardly beside the pro-proliferative, anti-apoptotic effects reported in heart tissue, and how one peptide would do both has not been explained. The AEDR-specific mechanistic data are modest. In mouse embryonic fibroblasts it raised cytoskeletal proteins (actin, tubulin, vimentin) 2 to 5 times and the nuclear lamins A and C 2 to 3 times, which the authors tie to its reported cardioprotective activity. In cell-free tests it bound wheat histone proteins. Computer docking suggests it could fit the LAT1, LAT2 and PEPT1 transporters that carry amino acids and small peptides into cells, and a 2022 review lists AEDR among peptides proposed to regulate inflammaging in cardiovascular cells. Human cardiomyocyte data, structural data on DNA binding in heart cells, and any identified receptor are absent.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Cardiogen:

• 01Independent analytical testing of products sold as Cardiogen — the developer's patent defines the sequence as Ala-Glu-Asp-Arg (AEDR), but no independent lab has published tests of whether research-chemical vials or the Russian 'peptide complex' capsules contain AEDR at the stated amount, and many vendors still mislabel it as the tripeptide AED.
• 02Peer-reviewed publication of the developer's patent experiments — the rat heart-attack mortality, isolated-heart, arrhythmia and 6-month toxicity data for AEDR exist only in the patent, including signs that higher concentrations worsened heart contraction after ischemia and that only a middle dose worked best in the arrhythmia model.
• 03Independent Western preclinical replication of the age-dependent myocardial proliferation finding by a cardiology or structural-biology laboratory operating outside the Khavinson research orbit, without which the entire single-research-orbit pattern remains unresolved.
• 04Any randomized controlled trial in humans, in any cardiovascular indication, at any dose, by any route — the complete absence of human controlled data is the single largest gap and the one that most directly limits what can honestly be said about the peptide.
• 05Human pharmacokinetic characterization — absorption (especially from the Russian-market oral capsule product), distribution, whether the intact tetrapeptide reaches cardiac tissue in any meaningful concentration after oral or subcutaneous administration, metabolism, and elimination kinetics are all unknown.
• 06A concrete molecular mechanism for the claimed tissue specificity — how a four-residue peptide is supposed to recognize myocardial DNA regulatory regions selectively over those in other tissues has not been worked out structurally or functionally even within the Khavinson literature, let alone independently.
• 07Replication of the tumor-growth inhibition reported in old rats with M-1 sarcoma — dose-dependence, tumor-type dependence, the proposed blood-vessel mechanism, and whether it generalizes beyond that single model — given that this is one of the only Cardiogen-specific findings outside the explicit cardiac context.
• 08Long-term safety data in animals with structural heart disease (post-infarct, hypertrophic, or failing myocardium), since extrapolating from healthy-rodent proliferation data to diseased human hearts is exactly the inferential leap the existing evidence cannot support.
• 09Honest head-to-head comparison data against standard cardiology pharmacotherapy — not because any such comparison is realistic in the near term, but because in its absence the implicit framing of Cardiogen as a cardiovascular intervention substantially overstates its position.

Forms & Administration

Cardiogen reaches users through two primary channels: Russian-market Kardiogen oral capsules registered as a dietary supplement, and Western research-chemical injectable lyophilized powder labeled 'not for human use.' The Russian supplement leaflet lists 100 mcg of Cardiogen per capsule and suggests 1 to 2 capsules 1 to 2 times a day with meals for 20 to 30 days, repeated after 4 to 6 months; this is a supplement label, not a dose tested in a clinical trial. Injectable figures that circulate online (often around 100 to 200 mcg per dose, reconstituted in bacteriostatic water) are vendor conventions, not doses derived from any published study; the developer's rat heart-attack experiment used 0.05 mcg per rat by injection. No Western clinician operates a validated Cardiogen protocol. All peptides should only be used under the guidance of a qualified healthcare provider — and for any cardiovascular condition, standard cardiology care is dramatically better evidenced than Cardiogen. Never self-administer without clinician oversight.

Common Questions

Who Cardiogen Is NOT For

Drug & Supplement Interactions

There are no formally characterized drug interactions for Cardiogen because there are no human pharmacokinetic studies, no human clinical trials, and no interaction studies of any kind. All discussion of drug interactions is therefore theoretical and should be treated as such. The most relevant practical concern is not a pharmacokinetic interaction in the conventional sense but a clinical-care displacement risk: if a user with cardiovascular disease leans on Cardiogen instead of titrating their actual cardiology regimen (beta-blockers, ACE inhibitors or ARBs, statins, antiplatelet therapy, anticoagulants where indicated, diuretics in heart failure), the resulting under-treatment of the underlying condition is a far more concrete threat than any direct molecular interaction. If a short-peptide bioregulator did genuinely modulate cardiomyocyte gene expression as claimed, theoretical concerns would include unintended effects on cardiac conduction in patients on antiarrhythmics, potential interactions with electrophysiologically active drugs, and unpredictable effects on remodeling in patients on heart-failure pharmacotherapy — none of which have been studied. Coadministration with any cardiovascular prescription medicine should be treated as uncharacterized; cardiology pharmacotherapy should never be paused, reduced, or skipped to accommodate Cardiogen use, and any such decision belongs with the prescribing cardiologist, not with a peptide forum.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions